| 1.07 -0.03 (-2.73%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.4 | 1-year : | 1.54 |
| Resists | First : | 1.2 | Second : | 1.32 |
| Pivot price | 1.14 | |||
| Supports | First : | 1 | Second : | 0.84 |
| MAs | MA(5) : | 1.09 |
MA(20) : | 1.14 |
| MA(100) : | 1.44 |
MA(250) : | 1.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.5 | D(3) : | 29.5 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 3.05 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MIST ] has closed above bottom band by 22.6%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.12 |
| Low: | 1.03 - 1.04 | 1.04 - 1.05 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Tue, 18 Aug 2026
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Wed, 12 Aug 2026
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Wed, 12 Aug 2026
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Wed, 12 Aug 2026
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Wed, 12 Aug 2026
Milestone Pharmaceuticals: Q2 Earnings Snapshot - KTVB
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.1691e+008 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 10,600 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.514e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 942.4 % |
| Return on Equity (ttm) | -32 % |
| Qtrly Rev. Growth | 1.78e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -466.21 |
| EBITDA (p.s.) | 1.80612e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.88 |
| Dividend | 0 |
| Forward Dividend | 1.458e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|